GLP-1 Drugs Are Rewriting What We Know About Addiction, Alzheimer's, and Heart Disease

When GLP-1 receptor agonists were first approved for type 2 diabetes, the mechanism was well understood: the drugs mimic a gut hormone that stimulates insulin release and slows gastric emptying. What nobody fully anticipated was what happened when these same receptors were activated in the brain. The weight loss was striking. But it was the signals coming from unexpected corners of medicine -- addiction clinics, neurology wards, cardiology units -- that have turned GLP-1 drugs into one of the most broadly consequential drug classes in recent memory.

Quieting the Craving: Addiction Research

The largest study yet on GLP-1 drugs and addiction, published in The BMJ in March 2026, analyzed over 600,000 U.S. veterans. Patients taking GLP-1 medications showed a reduced risk of developing substance use disorders across every major addictive substance tested -- alcohol, cannabis, cocaine, nicotine, and opioids. Among patients already diagnosed with a substance use disorder, the drugs were associated with fewer hospitalizations, fewer overdoses, and fewer drug-related deaths.

The proposed mechanism mirrors what the drugs do with food: GLP-1 receptors in the brain's reward circuits appear to reduce "drug noise" -- the persistent background craving that makes abstinence so difficult to maintain. A separate clinical trial reported in May 2026 specifically tested semaglutide in patients with alcohol use disorder and found a significant reduction in alcohol consumption. The implication is that the same neural pathway driving compulsive eating may overlap substantially with the pathways driving compulsive drug use.

The Alzheimer's Question

The results on Alzheimer's disease have been more mixed. A major trial by Novo Nordisk testing oral semaglutide in patients with early Alzheimer's -- the EVOKE studies -- did not show a statistically significant slowing of disease progression. But a separate trial led by Imperial College London, testing liraglutide, published in Nature, reported nearly 50% less brain volume loss and an 18% slower decline in cognitive function.

The theoretical case for GLP-1 drugs in Alzheimer's remains compelling: they reduce neuroinflammation, improve brain insulin sensitivity, and appear to help clear toxic protein aggregates. Observational studies consistently show lower rates of cognitive decline in patients taking GLP-1 medications. Multiple ongoing trials will clarify the picture considerably over the next two years.

Cardiovascular: The Clearest Evidence

The cardiovascular evidence is the most robust. A large international review published in May 2026, covering over 90,000 patients, found GLP-1 drugs significantly reduce the risk of heart attacks, strokes, heart failure, and premature death -- independent of whether the patient has diabetes, with roughly a 13% reduction in major adverse cardiovascular events.

Research from the University of Bristol, published in Nature Communications in March 2026, identified a specific mechanism: GLP-1 drugs appear to prevent further tissue damage following a heart attack by improving blood flow in narrowed coronary capillaries. One important caveat: the cardiovascular benefits diminish if treatment is discontinued, with heart risks rising again within six months of stopping.

New Formulations and What Comes Next

Accessibility is changing. An oral Wegovy launched in the U.S. in January 2026, removing the injection barrier. A second oral GLP-1, orforglipron (Foundayo), was approved by the FDA in April 2026 without the strict food and water restrictions that complicate other oral options.

A new class targeting multiple hormone pathways simultaneously -- combining GLP-1 with GIP, glucagon, or amylin receptors -- is in final-stage testing, with approval expected in late 2026 or 2027. Early results suggest even greater therapeutic effects than current single-agonist drugs. What the expanding GLP-1 evidence base reveals is a drug class that happened to target a receptor system far more broadly important to human health than anyone initially appreciated.